Search results
Results from the WOW.Com Content Network
The most common abnormality the test can screen is trisomy 21 (Down syndrome).In addition to Down syndrome, the triple and quadruple screens assess risk for fetal trisomy 18 also known as Edwards syndrome, open neural tube defects, and may also detect an increased risk of Turner syndrome, triploidy, trisomy 16 mosaicism, fetal death, Smith–Lemli–Opitz syndrome, and steroid sulfatase ...
Second-trimester maternal serum screening (AFP screening, triple screen, quad screen, or penta screen) can check levels of alpha fetoprotein, β-hCG, inhibin-A, estriol, and h-hCG (hyperglycosolated hCG) in the woman's serum. The triple test measures serum levels of AFP, estriol, and beta-hCG, with a 70% sensitivity and 5% false-positive rate.
In this article, all values (except the ones listed below) denote blood plasma concentration, which is approximately 60–100% larger than the actual blood concentration if the amount inside red blood cells (RBCs) is negligible.
[7] [8] The AFP gene is located on the q arm of chromosome 4 (4q13.3). [9] Maternal AFP serum level is used to screen for Down syndrome, neural tube defects, and other chromosomal abnormalities. [10] AFP is a major plasma protein produced by the yolk sac and the fetal liver during fetal development. It is thought to be the fetal analog of serum ...
In plasma or serum (g/cm 3) Water: Solvent 0.81-0.86 ... Maintain calcium and phosphorus levels 1.7-4.1 × 10 −8: ... 4-10 × 10 −8: 17α-Hydroxyprogesterone ...
Blood compatibility testing is routinely performed before a blood transfusion.The full compatibility testing process involves ABO and RhD (Rh factor) typing; screening for antibodies against other blood group systems; and crossmatching, which involves testing the recipient's blood plasma against the donor's red blood cells as a final check for incompatibility.
Electronic cross-matching can only be used if a patient has a negative antibody screen, which means that they do not have any active red blood cell atypical antibodies, or they are below the detectable level of current testing methods. If all of the data entered is compatible, the computer will print a compatibility label stating that the unit ...
Other guidelines for the use of serum free light chain measurement in the management of AL amyloidosis, [42] plasmacytoma [43] and the comparison of treatment responses in clinical trials [44] have also been published. Technical and clinical reviews of serum free light-chain measurement have recently been written by Pratt and Jagannath. [45] [46]